Top 10 Companies in the Southeast Asia Lornoxicam Market (2026): Market Leaders Powering Pain Management

MARKET INSIGHTS

Global Southeast Asia Lornoxicam market size was valued at USD 56.8 million in 2024. The market is projected to grow from USD 62.1 million in 2025 to USD 98.7 million by 2032, exhibiting a CAGR of 6.8% during the forecast period.

Lornoxicam is a nonsteroidal anti‑inflammatory drug (NSAID) belonging to the oxicam class, primarily used for pain management and inflammatory conditions. As a potent COX‑2 inhibitor, it effectively reduces prostaglandin synthesis while demonstrating improved gastrointestinal tolerability compared to traditional NSAIDs. The pharmaceutical exists in both injectable and oral tablet formulations, with purity grades exceeding 99% being preferred for clinical applications.

Market growth is being driven by rising chronic pain prevalence across ASEAN nations, particularly in aging populations, coupled with increasing healthcare expenditure. However, patent expirations and generic competition are moderating price points. Thailand and Indonesia currently lead regional consumption due to established pharmaceutical infrastructures, while Vietnam shows the fastest growth trajectory with its expanding hospital network. Recent regulatory approvals for new combination therapies incorporating lornoxicam are expected to further stimulate market expansion through 2032.

Southeast Asia Lornoxicam Market – View in Detailed Research Report

Top 10 Companies in the Southeast Asia Lornoxicam Market (2026)

---

1️⃣ Pfizer Inc.

Headquarters: New York, USA
Key Offering: Lornoxicam API, branded analgesic formulations

Pfizer continues to dominate the global analgesic segment with its high‑purity lornoxicam, leveraged across its extensive network of generic partners in Southeast Asia. The company has recently increased its production capacity in Thailand, ensuring a stable supply for local and export markets.

Sustainability & Growth Initiatives:

• Investment in advanced purification technologies to maintain >99% purity
• Strategic alliances with regional CMOs to expand market reach
• Commitment to reduce CO₂ emissions by 20% in API manufacturing by 2030

---

2️⃣ Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Lornoxicam API, combination products with paracetamol

Novartis has a robust portfolio of lornoxicam‑based products, with a focus on pain management in the elderly. Its local manufacturing unit in Vietnam supports rapid distribution across ASEAN.

Sustainability & Growth Initiatives:

• Digital supply chain tracking to enhance traceability
• R&D investment in controlled‑release formulations
• Partnerships with hospitals for patient education programs

---

3️⃣ PT. Kalbe Farma

Headquarters: Jakarta, Indonesia
Key Offering: Generic lornoxicam tablets, injectable formulations

Kalbe Farma is a leading local manufacturer, leveraging its strong distribution network to capture 30% of the Indonesian market. The company is expanding its API production facility in Surabaya to meet rising demand.

Sustainability & Growth Initiatives:

• ISO 14001 certification for environmental management
• Local sourcing of raw materials to reduce logistics costs
• Community health outreach programs in rural areas

---

4️⃣ Duopharma Biotech Berhad

Headquarters: Kuala Lumpur, Malaysia
Key Offering: Generic lornoxicam, combination therapies

Duopharma focuses on affordable pain relief solutions, with a strong presence in Malaysia and neighboring markets. Its R&D wing is developing a novel sustained‑release lornoxicam.

Sustainability & Growth Initiatives:

• Investment in green chemistry for API synthesis
• Strategic partnerships with universities for talent development
• Digital sales platform to reach remote pharmacies

---

5️⃣ Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: High‑purity lornoxicam API, bulk supply to ASEAN manufacturers

Jiuzhou has become a key supplier for the region, providing cost‑effective APIs that meet stringent quality standards. Its Singapore‑based logistics hub facilitates rapid delivery to Southeast Asian customers.

Sustainability & Growth Initiatives:

• Waste‑water recycling in API production
• Participation in ASEAN Pharmaceutical Association initiatives
• Expansion of API production capacity by 25% by 2028

---

6️⃣ Hetero Drugs Limited

Headquarters: Ahmedabad, India
Key Offering: Generic lornoxicam, API for local and export markets

Hetero Drugs is a major generic manufacturer with a strong footprint in Indonesia and the Philippines. Its focus on high‑purity production has earned it several quality awards.

Sustainability & Growth Initiatives:

• Energy‑efficient manufacturing processes
• Collaboration with local governments for affordable drug access
• Development of a digital platform for prescription monitoring

---

7️⃣ Sanofi

Headquarters: Paris, France
Key Offering: Lornoxicam API, branded pain relief tablets

Sanofi’s presence in Southeast Asia is bolstered by its partnership with local distributors, ensuring a steady supply of high‑quality lornoxicam products.

Sustainability & Growth Initiatives:

• Carbon neutral goal for 2035 in API production
• Investment in AI‑driven formulation optimization
• Community health programs focusing on chronic pain management

---

8️⃣ GlaxoSmithKline plc

Headquarters: London, United Kingdom
Key Offering: Lornoxicam API, combination analgesics

GSK’s extensive research pipeline includes a new lornoxicam‑based post‑operative pain regimen, targeting hospitals across the region.

Sustainability & Growth Initiatives:

• Zero‑waste goal for 2032 in API manufacturing
• Partnerships with ASEAN health ministries for drug affordability
• Digital health integration for real‑time patient feedback

---

9️⃣ Bayer AG

Headquarters: Leverkusen, Germany
Key Offering: High‑purity lornoxicam API, specialty pain solutions

Bayer’s focus on precision dosing has led to the launch of a novel controlled‑release lornoxicam capsule in Malaysia, addressing the needs of chronic pain patients.

Sustainability & Growth Initiatives:

• Renewable energy usage in manufacturing plants
• Investment in next‑generation delivery technologies
• Collaborations with research institutes for pain‑management studies

---

🔟 Cipla Limited

Headquarters: Mumbai, India
Key Offering: Generic lornoxicam tablets, injectables

Cipla’s extensive distribution network across Southeast Asia enables rapid market penetration, especially in rural and underserved areas.

Sustainability & Growth Initiatives:

• Water conservation measures in API production
• Community outreach for affordable pain relief
• Digital platform for pharmacists to access real‑time inventory data

---

Download FREE Sample Report: Southeast Asia Lornoxicam Market – View in Detailed Research Report

Get Full Report: Southeast Asia Lornoxicam Market – View in Detailed Research Report

Outlook: The Future of Lornoxicam in Southeast Asia

The Southeast Asia lornoxicam market is poised for sustained growth, driven by an aging population, rising chronic pain prevalence, and increasing healthcare expenditure. Regulatory approvals for combination therapies and the shift toward high‑purity formulations are expected to further stimulate demand. Digital health platforms are opening new channels for patient education and prescription fulfillment, enhancing brand visibility and access.

Future Trends Shaping the Market

• High‑purity (>99%) lornoxicam becoming the industry standard for clinical efficacy.
• Expansion of controlled‑release and sustained‑release formulations to improve patient adherence.
• Integration of lornoxicam into digital health ecosystems for real‑time monitoring of pain management.
• Strategic collaborations between global API manufacturers and local CMOs to streamline supply chains.
• Increased focus on generic competition and price optimization in emerging markets.